IBRX ImmunityBio, Inc.Stock Price & Overview
$4.82
Charts
Quant Ranking
IBRX Analysis
IBRX News
Latest Headlines
Ratings Summary
People Also Follow
Similar to IBRX
ETFs Holding IBRX
IBRX Company Profile
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
IBRX Revenue
IBRX Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
IBRX Ownership
IBRX Peers
Risk
Technicals
Investor Presentations
IBRX SEC Filings
Press Releases
IBRX Income Statement
IBRX Balance Sheet
IBRX Cash Flow Statement
IBRX Long Term Solvency
Discover More
You may be interested in: